Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Losseff, N A
Right arrow Articles by Thompson, A J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Losseff, N A
Right arrow Articles by Thompson, A J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 7, No. 1, 23-25 (2001)
DOI: 10.1177/135245850100700105

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

N A Losseff

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

D H Miller

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

D Kidd

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

A J Thompson

NMR Research Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK

As short-term MRI studies are increasingly being used to monitor disease activity in multiple sclerosis (MS) it is vital to establish if short-term MRI activity is predictive of long term clinical outcome. We followed up after 5 years a group of 10 benign (relapsing-remitting MS with a disease duration 410 years and EDSS 43) and 10 early relapsing-remitting patients who previously had monthly serial MRI scans for 6 months. In the early relapsing-remitting group median EDSS at entry to the initial serial study was three and in the benign group 2.5. At 5-year follow up, five of these 20 patients had developed a definite deterioration in EDSS. The median number of new enhancing lesions detected originally in the group that had deteriorated was 11 (7-17) compared to 0 (0-5) new enhancing lesions, for those who had not deteriorated (P50.05). There was a trend towards a higher baseline T2 lesion load in the group with a definite change in EDSS but this was not significant. This study suggests that short-term measurement of the number of gadolinium enhancing lesions may predict long term outcome in relapsing-remitting MS.

Key Words: MS • enhancement • prediction • disability


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mult SclerHome page
W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study
Multiple Sclerosis, March 1, 2007; 13(2): 178 - 185.
[Abstract] [PDF]


Home page
NeurologyHome page
F. Cotton, H. L. Weiner, F. A. Jolesz, and C. R.G. Guttmann
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals
Neurology, February 25, 2003; 60(4): 640 - 646.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. L. Arnold and P.M. Matthews
MRI in the diagnosis and management of multiple sclerosis
Neurology, April 23, 2002; 58(90084): S23 - 31.
[Abstract] [Full Text]